Evaxion Biotech Reports Positive EVX-01 Vaccine Data at AACR Meeting

Evaxion Biotech ( (EVAX) ) has issued an announcement.

On April 28, 2025, Evaxion Biotech announced promising data from its phase 2 trial of the personalized cancer vaccine EVX-01, presented at the AACR Annual Meeting. The data revealed that 80% of the vaccine targets triggered a tumor-reactive immune response, a significant improvement from previous analyses. This underscores the precision of Evaxion’s AI-Immunology™ platform in selecting effective vaccine targets. The trial, which combines EVX-01 with Merck’s KEYTRUDA® for advanced melanoma, remains on track for a two-year data readout in the latter half of 2025, with a third-year extension planned to further explore the vaccine’s potential.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Underperform.

Evaxion Biotech’s overall score reflects a company with strong revenue growth and strategic partnerships but facing significant financial instability and technical challenges. Despite an optimistic earnings call, persistent losses and valuation concerns weigh heavily on the stock’s performance.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion Biotech A/S is a clinical-stage TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company leverages its proprietary AI platform to create novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion’s pipeline includes personalized vaccines for oncology and preclinical candidates for infectious diseases, aiming to address high unmet medical needs.

YTD Price Performance: -60.96%

Average Trading Volume: 1,302,097

Technical Sentiment Signal: Buy

Current Market Cap: $2.31M

For an in-depth examination of EVAX stock, go to TipRanks’ Stock Analysis page.